Multi-factor Evaluation of Tumor-infiltrating Lymphocytes in Laryngeal Squamous Cell Carcinoma and its Prognostic Value

Background: Laryngeal squamous cell carcinoma (LSCC) is a heterogeneous disease. In clinical practice, patients with similar clinicopathological characteristics often show different outcomes. This study evaluated the levels of primary LSCC intratumoral infiltrating lymphocytes (iTILs), tumor-infiltrating lymphocyte volume (TILV), frontier tumor-infiltrating lymphocytes (fTILs), and their relations to the patient's clinical outcome. Materials and methods: According to the 2017 study of the International TILs Working Group, hematoxyline and eosin-stained slides from 412 patients were evaluated for their morphology of tumor immune infiltration status.Results: Kaplan-Meier analysis showed that high levels of iTILs, TILV, and fTILs were significantly correlated with OS (all P<0.05). Cox regression model analysis showed that high levels of iTILs, TILV, and fTILs were independently associated with better OS (all P<0.05). Conclusion: Local inflammatory markers in patients with laryngeal squamous cell carcinoma, especially the levels of iTILs, TILV, and fTILs, are reliable prognostic factors.

[1]  S. Lockett,et al.  Collective cancer cell invasion requires RNA accumulation at the invasive front , 2020, Proceedings of the National Academy of Sciences.

[2]  Junyi He,et al.  Elevated ZBTB7A expression in the tumor invasive front correlates with more tumor budding formation in gastric adenocarcinoma , 2020, Journal of Cancer Research and Clinical Oncology.

[3]  A. Zerbi,et al.  Immune infiltrating cells in duodenal cancers , 2020, Journal of translational medicine.

[4]  I. Endo,et al.  CD8 T Cell Score as a Prognostic Biomarker for Triple Negative Breast Cancer , 2020, International journal of molecular sciences.

[5]  Xin Huang,et al.  Anti-cancer effect of miR-139-3p on laryngeal squamous cell carcinoma by targeting rab5a: In vitro and in vivo studies. , 2020, Pathology, research and practice.

[6]  Mingchen Xiong,et al.  Cancer-associated adipocytes: emerging supporters in breast cancer , 2020, Journal of Experimental & Clinical Cancer Research.

[7]  H. Cao,et al.  miR-375-3p inhibits the progression of laryngeal squamous cell carcinoma by targeting hepatocyte nuclear factor-1β , 2020, Oncology letters.

[8]  Gang Yin,et al.  Integrated Analysis of Prognostic and Immune Associated Integrin Family in Ovarian Cancer , 2020, Frontiers in Genetics.

[9]  Zhiyong Yuan,et al.  Abnormal spindle-like microcephaly-associated protein (ASPM) contributes to the progression of Lung Squamous Cell Carcinoma (LSCC) by regulating CDK4 , 2020, Journal of Cancer.

[10]  Jun Shen,et al.  A gene signature associated with prognosis and immune processes in head and neck squamous cell carcinoma , 2019, Head & neck.

[11]  F. Peyrade,et al.  Immunotherapy in recurrent and or metastatic squamous cell carcinoma of the head and neck , 2019, Current opinion in oncology.

[12]  Songlin Zhang,et al.  Reproducible evaluation of tumor-infiltrating lymphocytes (TILs) using the recommendations of International TILs Working Group 2014. , 2018, Annals of diagnostic pathology.

[13]  K. Harrington,et al.  Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression. , 2018, Oral oncology.

[14]  T. Nielsen,et al.  Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer. , 2017, Seminars in cancer biology.

[15]  T. Seiwert,et al.  Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  Wenjiao Zeng,et al.  The prognostic value of systemic and local inflammation in patients with laryngeal squamous cell carcinoma , 2016, OncoTargets and therapy.

[17]  Su Jin Heo,et al.  PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor for head and neck cancer patients , 2016, Scientific Reports.

[18]  S. Agelaki,et al.  The promise of immunotherapy in head and neck squamous cell carcinoma. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[19]  A. Scorilas,et al.  Evaluation of PD-L1 Expression and Associated Tumor-Infiltrating Lymphocytes in Laryngeal Squamous Cell Carcinoma , 2015, Clinical Cancer Research.

[20]  Carsten Denkert,et al.  Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  J. Pollard,et al.  Immune cell promotion of metastasis , 2015, Nature Reviews Immunology.

[22]  P. Michelozzi,et al.  Tumor-infiltrating lymphocytes predict cutaneous melanoma survival , 2015, Journal of Translational Medicine.

[23]  A. Eisbruch,et al.  Biomarkers in advanced larynx cancer , 2014, The Laryngoscope.

[24]  F. Marincola,et al.  Towards the introduction of the ‘Immunoscore’ in the classification of malignant tumours , 2013, The Journal of pathology.

[25]  E. King,et al.  Tumour-infiltrating lymphocytes predict for outcome in HPV-positive oropharyngeal cancer , 2013, British Journal of Cancer.

[26]  F. Marincola,et al.  Cancer classification using the Immunoscore: a worldwide task force , 2012, Journal of Translational Medicine.

[27]  L. Giacomelli,et al.  Glottic laser surgery: outcomes according to 2007 ELS classification , 2011, European Archives of Oto-Rhino-Laryngology.

[28]  E. Nkenke,et al.  Tumour infiltrating lymphocytes in squamous cell carcinoma of the oro- and hypopharynx: prognostic impact may depend on type of treatment and stage of disease. , 2009, Oral oncology.

[29]  G. Grabenbauer,et al.  Distribution of immune cells in head and neck cancer: CD8+ T-cells and CD20+ B-cells in metastatic lymph nodes are associated with favourable outcome in patients with oro- and hypopharyngeal carcinoma , 2009, BMC Cancer.

[30]  K. Higgins,et al.  An update on larynx cancer , 2017, CA: a cancer journal for clinicians.